Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00228605 · ClinicalTrials.gov registry record · Phase 3
Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain
A Phase 3 study, sponsored by Cephalon.
- Completed
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
NCT00228605 is a Phase 3 study that has completed, run by Cephalon. The registered enrollment target is 500 participants.
The verdict
NCT00228605, a Phase 3 study, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
Interventions
- DRUG OraVescent Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2005-03 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00228605
The ClinicalTrials.gov registry entry for NCT00228605 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OraVescent Fentanyl is the first listed.
NCT00228605 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00228605 about?
NCT00228605 is a clinical study titled "Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain". The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl for the potential treatment of breakthrough pain episodes in patients who have chronic noncancer pain.
What is the current status of trial NCT00228605?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2005-03. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00228605?
The interventions under investigation include: OraVescent Fentanyl (DRUG).
Who is sponsoring clinical trial NCT00228605?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.